Dexpramipexole dihydrochloride Catalog No.:M9926-2 A-438079 partially but significantly prevented

A-438079 partially but significantly prevented the 6-OHDA-induced depletion of striatal DA stores

AG14361 markedly enhances NSC 362856 activity against LoVo xenografts and delays tumor growth when combined with NSC 362856

which shows significant inhibitory activity towards LTA4 hydrolase with IC50 of 8 nM

2017 Jan 6

Dexpramipexole dihydrochloride Catalog No.:M9926-2 A-438079 partially but significantly preventedDexpramipexole, also known as KNS 760704 and (R) Pramipexole, is under development for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrigs disease. The drug failed to show efficacy in terms of function or survival in a Phase III study of patients with ALS. Dexpramipexole is a low molecular weight, water soluble, orally bioavailable, renally excreted compound with linear pharmacokinetics, and has been shown to be well